Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients
Abstract Background 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients bo...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2019-01-01
|
Series: | EJNMMI Physics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40658-018-0239-2 |
id |
doaj-b79978a90bfb4852af48633cdb9d1498 |
---|---|
record_format |
Article |
spelling |
doaj-b79978a90bfb4852af48633cdb9d14982020-11-24T21:21:17ZengSpringerOpenEJNMMI Physics2197-73642019-01-016111110.1186/s40658-018-0239-2Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patientsKristina Sandgren0Lennart Johansson1Jan Axelsson2Joakim Jonsson3Mattias Ögren4Margareta Ögren5Martin Andersson6Sara Strandberg7Tufve Nyholm8Katrine Riklund9Anders Widmark10Department of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Diagnostic Radiology, Umeå UniversityDepartment of Radiation Sciences, Diagnostic Radiology, Umeå UniversityDepartment of Medical Radiation Physics, ITM, Lund UniversityDepartment of Radiation Sciences, Diagnostic Radiology, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityDepartment of Radiation Sciences, Diagnostic Radiology, Umeå UniversityDepartment of Radiation Sciences, Radiation Physics, Umeå UniversityAbstract Background 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients both in the primary and secondary stages of prostate cancer. The aim of this study was to determine the effective dose and organ doses from injection of [68Ga]PSMA-11 in a cohort of low-risk prostate cancer patients. Methods Six low-risk prostate cancer patients were injected with 133–178 MBq [68Ga]PSMA-11 and examined with four PET/CT acquisitions from injection to 255 min post-injection. Urine was collected up to 4 h post-injection, and venous blood samples were drawn at 45 min, 85 min, 175 min, and 245 min post-injection. Kidneys, liver, lungs, spleen, salivary and lacrimal glands, and total body where delineated, and cumulated activities and absorbed organ doses calculated. The software IDAC-Dose 2.1 was used to calculate absorbed organ doses according to the International Commission on Radiological Protection (ICRP) publication 107 using specific absorbed fractions published in ICRP 133 and effective dose according to ICRP Publication 103. We also estimated the absorbed dose to the eye lenses using Monte Carlo methods. Results [68Ga]PSMA-11 was rapidly cleared from the blood and accumulated preferentially in the kidneys and the liver. The substance has a biological half-life in blood of 6.5 min (91%) and 4.4 h (9%). The effective dose was calculated to 0.022 mSv/MBq. The kidneys received approximately 40 mGy after an injection with 160 MBq [68Ga]PSMA-11 while the lacrimal glands obtained an absorbed dose of 0.12 mGy per administered MBq. Regarding the eye lenses, the absorbed dose was low (0.0051 mGy/MBq). Conclusion The effective dose for [68Ga]PSMA-11 is 0.022 mSv/MBq, where the kidneys and lacrimal glands receiving the highest organ dose.http://link.springer.com/article/10.1186/s40658-018-0239-2Radiation dosimetry[68Ga]PSMA-11PSMAPET-tracerProstate cancerAbsorbed dose and effective dose |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kristina Sandgren Lennart Johansson Jan Axelsson Joakim Jonsson Mattias Ögren Margareta Ögren Martin Andersson Sara Strandberg Tufve Nyholm Katrine Riklund Anders Widmark |
spellingShingle |
Kristina Sandgren Lennart Johansson Jan Axelsson Joakim Jonsson Mattias Ögren Margareta Ögren Martin Andersson Sara Strandberg Tufve Nyholm Katrine Riklund Anders Widmark Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients EJNMMI Physics Radiation dosimetry [68Ga]PSMA-11 PSMA PET-tracer Prostate cancer Absorbed dose and effective dose |
author_facet |
Kristina Sandgren Lennart Johansson Jan Axelsson Joakim Jonsson Mattias Ögren Margareta Ögren Martin Andersson Sara Strandberg Tufve Nyholm Katrine Riklund Anders Widmark |
author_sort |
Kristina Sandgren |
title |
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients |
title_short |
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients |
title_full |
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients |
title_fullStr |
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients |
title_full_unstemmed |
Radiation dosimetry of [68Ga]PSMA-11 in low-risk prostate cancer patients |
title_sort |
radiation dosimetry of [68ga]psma-11 in low-risk prostate cancer patients |
publisher |
SpringerOpen |
series |
EJNMMI Physics |
issn |
2197-7364 |
publishDate |
2019-01-01 |
description |
Abstract Background 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC ([68Ga]PSMA-11) has been increasingly used to image prostate cancer using positron emission tomography (PET)/computed tomography (CT) both during diagnosis and treatment planning. It has been shown to be of clinical value for patients both in the primary and secondary stages of prostate cancer. The aim of this study was to determine the effective dose and organ doses from injection of [68Ga]PSMA-11 in a cohort of low-risk prostate cancer patients. Methods Six low-risk prostate cancer patients were injected with 133–178 MBq [68Ga]PSMA-11 and examined with four PET/CT acquisitions from injection to 255 min post-injection. Urine was collected up to 4 h post-injection, and venous blood samples were drawn at 45 min, 85 min, 175 min, and 245 min post-injection. Kidneys, liver, lungs, spleen, salivary and lacrimal glands, and total body where delineated, and cumulated activities and absorbed organ doses calculated. The software IDAC-Dose 2.1 was used to calculate absorbed organ doses according to the International Commission on Radiological Protection (ICRP) publication 107 using specific absorbed fractions published in ICRP 133 and effective dose according to ICRP Publication 103. We also estimated the absorbed dose to the eye lenses using Monte Carlo methods. Results [68Ga]PSMA-11 was rapidly cleared from the blood and accumulated preferentially in the kidneys and the liver. The substance has a biological half-life in blood of 6.5 min (91%) and 4.4 h (9%). The effective dose was calculated to 0.022 mSv/MBq. The kidneys received approximately 40 mGy after an injection with 160 MBq [68Ga]PSMA-11 while the lacrimal glands obtained an absorbed dose of 0.12 mGy per administered MBq. Regarding the eye lenses, the absorbed dose was low (0.0051 mGy/MBq). Conclusion The effective dose for [68Ga]PSMA-11 is 0.022 mSv/MBq, where the kidneys and lacrimal glands receiving the highest organ dose. |
topic |
Radiation dosimetry [68Ga]PSMA-11 PSMA PET-tracer Prostate cancer Absorbed dose and effective dose |
url |
http://link.springer.com/article/10.1186/s40658-018-0239-2 |
work_keys_str_mv |
AT kristinasandgren radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT lennartjohansson radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT janaxelsson radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT joakimjonsson radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT mattiasogren radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT margaretaogren radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT martinandersson radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT sarastrandberg radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT tufvenyholm radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT katrineriklund radiationdosimetryof68gapsma11inlowriskprostatecancerpatients AT anderswidmark radiationdosimetryof68gapsma11inlowriskprostatecancerpatients |
_version_ |
1725999875579969536 |